DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
20.99
-0.53 (-2.46%)
At close: Feb 27, 2026, 4:00 PM EST
20.58
-0.41 (-1.95%)
After-hours: Feb 27, 2026, 7:32 PM EST
DBV Technologies Revenue
DBV Technologies had revenue of $2.77M in the quarter ending September 30, 2025, with 158.77% growth. This brings the company's revenue in the last twelve months to $5.50M, down -56.04% year-over-year. In the year 2024, DBV Technologies had annual revenue of $4.15M, down -73.61%.
Revenue (ttm)
$5.50M
Revenue Growth
-56.04%
P/S Ratio
227.65
Revenue / Employee
$47,026
Employees
117
Market Cap
1.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.15M | -11.58M | -73.61% |
| Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
| Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
| Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
| Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 362.27M |
| Immatics | 99.45M |
| Septerna | 22.05M |
| Inventiva | 19.93M |
| Taysha Gene Therapies | 6.31M |
| Precigen | 6.31M |
| AtaiBeckley | 3.02M |
DBVT News
- 10 hours ago - DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - GlobeNewsWire
- 17 days ago - DBV Technologies To Present Additional VITESSE Phase 3 Data In Peanut-Allergic Children - Nasdaq
- 18 days ago - DBV Technologies S.A.: DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting - Finanz Nachrichten
- 18 days ago - DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting - Wallstreet:Online
- 18 days ago - DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting - GlobeNewsWire
- 19 days ago - DBV Technologies S.A.: DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit - Finanz Nachrichten
- 23 days ago - DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 - Finanz Nachrichten
- 23 days ago - Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 - GlobeNewsWire